Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Santegoets et al.; licensee BioMed Central Ltd. 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

High pretreatment frequency of mMDSC is associated with reduced OS. mMDSC frequencies were determined before (week 0/visit 1 (w0v1)), during (w8v5, w16v9 and w24v13) and after (follow-up (fu)) prostate GVAX/ipilimumab therapy by flow cytometry. A) A representative analysis of Lin⁻CD14⁺HLA-DR^−/lo mMDSC. B) Percentage of mMDSC over follow-up. C) Kaplan meier curve for pre-treatment frequencies of mMDSC. Number of patients and corresponding median survival for each group are given. Differences between pre- and on- or post-treatment were analyzed with the repeated measures ANOVA with a post-hoc Dunnett’s multiple comparisons test. Differences were considered significant when p < 0.05, as indicated with asterisks (* p < 0.05, ** p < 0.01). Statistical significance of the survival distribution was analyzed by log-rank testing and indicated with the given p-value.